Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

myCare-102: A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

NCT05693831 is registered in ClinicalTrials.gov with Cellworks Group Inc. as lead sponsor.

NCT NCT05693831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05693831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
myCare-102: A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
Lead sponsor
Cellworks Group Inc.
Phase
Observational
Overall status
Unknown status
Start date
December 1, 2022
Completion date
December 1, 2025
Enrollment
730 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, refractory cancer, relapsed cancer